Media stories about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.974481935973 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- ACADIA Pharmaceuticals (ACAD) & Beyondspring (BYSI) Financial Comparison (americanbankingnews.com)
- Hot Stock in Focus – ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) – Alpha Beta Stock (alphabetastock.com)
- ACADIA Pharmaceuticals Inc. (ACAD): Ownership and Basic Trading Data – Market Movers (financialqz.com)
- Technical data gathered from ACADIA Pharmaceuticals Inc. (ACAD) – Wall Street Morning (wallstreetmorning.com)
- ACADIA Pharmaceuticals (ACAD) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, November 8th. JPMorgan Chase & Co. set a $50.00 price target on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 5th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $61.00 target price (up previously from $54.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 5th. JMP Securities upped their target price on ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. Finally, ValuEngine downgraded ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. ACADIA Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $48.86.
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at $26.92 on Friday. ACADIA Pharmaceuticals has a 12 month low of $25.06 and a 12 month high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The firm had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. During the same period in the prior year, the company earned ($0.61) earnings per share. The company’s quarterly revenue was up 571.3% on a year-over-year basis. equities analysts anticipate that ACADIA Pharmaceuticals will post -2.41 EPS for the current year.
In other news, Director Laura Brege sold 25,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $30.06, for a total value of $751,500.00. Following the completion of the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $450,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Glenn Baity sold 74,321 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $30.14, for a total value of $2,240,034.94. The disclosure for this sale can be found here. 22.25% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://ledgergazette.com/2018/01/21/acadia-pharmaceuticals-acad-receives-daily-coverage-optimism-score-of-0-15.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.